Elissa S. Cote - 23 Jun 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Role
Chief Corp Development Officer
Signature
/s/ Cynthia Anderson, Attorney-in-Fact
Issuer symbol
VTGN
Transactions as of
23 Jun 2025
Net transactions value
$0
Form type
4
Filing time
25 Jun 2025, 17:16:37 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cote Elissa S. Chief Corp Development Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO /s/ Cynthia Anderson, Attorney-in-Fact 25 Jun 2025 0002069951

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTGN Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 23 Jun 2025 Common Stock 150,000 $1.96 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the stock options vest on June 23, 2026 (the "Vesting Start Date") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date.
F2 The stock options were granted in connection with the Reporting Person's appointment as Chief Corporate Development Officer.